Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Enzon Pharms Inc (ENZN)

Enzon Pharms Inc (ENZN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 4,497
  • Shares Outstanding, K 74,215
  • Annual Sales, $ 30 K
  • Annual Income, $ 780 K
  • EBIT $ -4 M
  • EBITDA $ -4 M
  • 60-Month Beta 0.20
  • Price/Sales N/A
  • Price/Cash Flow 5.97
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.05
  • Most Recent Earnings $-0.02 on 11/12/25
  • Next Earnings Date 05/08/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend 0.240 on 09/30/19
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0551 +9.98%
on 02/25/26
0.0751 -19.31%
on 02/05/26
-0.0134 (-18.11%)
since 02/04/26
3-Month
0.0310 +95.48%
on 12/30/25
0.0790 -23.29%
on 02/02/26
+0.0168 (+38.36%)
since 12/04/25
52-Week
0.0310 +95.48%
on 12/30/25
0.1299 -53.35%
on 06/30/25
-0.0549 (-47.53%)
since 03/04/25

Most Recent Stories

More News
Enzon Announces Extension of Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock

CRANFORD, N.J., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) (“ Enzon ” or the “ Company ”) today announced that it has extended the expiration date for the exchange...

ENZN : 0.0606 (-3.19%)
Enzon Announces Commencement of Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock in Connection With Viskase Merger

CRANFORD, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) (“Enzon” or the “Company”), today announced that it has commenced an exchange offer (the “Offer”)...

ENZN : 0.0606 (-3.19%)
$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--DHIL, TBN, CEPT, and ENZN

NEW YORK , Jan. 29, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars...

TBN : 31.00 (unch)
DHIL : 172.08 (+0.20%)
CEPT : 11.10 (-0.98%)
ENZN : 0.0606 (-3.19%)
SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Enzon Pharmaceuticals, Inc. (OTCMKTS: ENZN)

NEW YORK , Oct. 27, 2025 /PRNewswire/ -- Class Action Attorney  Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions...

ENZN : 0.0606 (-3.19%)
Enzon and Viskase Announce Amendment to Merger Agreement

CRANFORD, N.J. and LOMBARD, Ill., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) (“ Enzon ” or the “ Company ”) and Viskase Companies, Inc. (OTC Pink Limited: VKSC)...

ENZN : 0.0606 (-3.19%)
VKSC : 0.4500 (unch)
Enzon and Viskase Enter into Merger Agreement

ENZN : 0.0606 (-3.19%)

Business Summary

Enzon Pharmaceuticals, Inc. is a biotechnology company. It discovers, develops, and commercializes therapeutics to treat life-threatening diseases. The Company's marketed drug products include PegIntron (R) for chronic hepatitis C; Sylatron (R) for Melanoma; Macugen (R) for neovascular age-related macular...

See More

Key Turning Points

3rd Resistance Point 0.0669
2nd Resistance Point 0.0657
1st Resistance Point 0.0631
Last Price 0.0606
1st Support Level 0.0593
2nd Support Level 0.0581
3rd Support Level 0.0555

See More

52-Week High 0.1299
Fibonacci 61.8% 0.0921
Fibonacci 50% 0.0804
Fibonacci 38.2% 0.0688
Last Price 0.0606
52-Week Low 0.0310

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar